These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


Pubmed for Handhelds

PUBMED FOR HANDHELDS

Journal Abstract Search

313 related items for PubMed ID: 31304823

  • 1. Differential insulin response to oral glucose tolerance test (OGTT) in overweight/obese polycystic ovary syndrome patients undergoing to myo-inositol (MYO), alpha lipoic acid (ALA), or combination of both.
    Genazzani AD, Prati A, Marchini F, Petrillo T, Napolitano A, Simoncini T.
    Gynecol Endocrinol; 2019 Dec; 35(12):1088-1093. PubMed ID: 31304823
    [Abstract] [Full Text] [Related]

  • 2. Familial diabetes predisposes PCOS patients to insulin resistance (IR), reproductive impairment and hepatic dysfunction: effects of d-chiro inositol (DCI) and alpha lipoic acid (ALA) administration on hepatic insulin extraction (HIE) index.
    Genazzani AD, Battipaglia C, Petrillo T, Piacquadio N, Ambrosetti F, Arnesano M, Semprini E, Sponzilli A, Tomatis V, Simoncini T.
    Gynecol Endocrinol; 2022 Aug; 38(8):681-688. PubMed ID: 35748584
    [Abstract] [Full Text] [Related]

  • 3. Endocrine and clinical effects of myo-inositol administration in polycystic ovary syndrome. A randomized study.
    Artini PG, Di Berardino OM, Papini F, Genazzani AD, Simi G, Ruggiero M, Cela V.
    Gynecol Endocrinol; 2013 Apr; 29(4):375-9. PubMed ID: 23336594
    [Abstract] [Full Text] [Related]

  • 4. Differential insulin response to myo-inositol administration in obese polycystic ovary syndrome patients.
    Genazzani AD, Prati A, Santagni S, Ricchieri F, Chierchia E, Rattighieri E, Campedelli A, Simoncini T, Artini PG.
    Gynecol Endocrinol; 2012 Dec; 28(12):969-73. PubMed ID: 22612517
    [Abstract] [Full Text] [Related]

  • 5. Myo-inositol administration positively affects hyperinsulinemia and hormonal parameters in overweight patients with polycystic ovary syndrome.
    Genazzani AD, Lanzoni C, Ricchieri F, Jasonni VM.
    Gynecol Endocrinol; 2008 Mar; 24(3):139-44. PubMed ID: 18335328
    [Abstract] [Full Text] [Related]

  • 6. Myo-inositol modulates insulin and luteinizing hormone secretion in normal weight patients with polycystic ovary syndrome.
    Genazzani AD, Santagni S, Ricchieri F, Campedelli A, Rattighieri E, Chierchia E, Marini G, Despini G, Prati A, Simoncini T.
    J Obstet Gynaecol Res; 2014 May; 40(5):1353-60. PubMed ID: 24606639
    [Abstract] [Full Text] [Related]

  • 7. Long-term treatment with α-lipoic acid and myo-inositol positively affects clinical and metabolic features of polycystic ovary syndrome.
    Fruzzetti F, Fidecicchi T, Palla G, Gambacciani M.
    Gynecol Endocrinol; 2020 Feb; 36(2):152-155. PubMed ID: 31317814
    [Abstract] [Full Text] [Related]

  • 8. Polycystic ovary syndrome (PCOS) and hyperandrogenism: the role of a new natural association.
    Morgante G, Cappelli V, Di Sabatino A, Massaro MG, De Leo V.
    Minerva Ginecol; 2015 Oct; 67(5):457-63. PubMed ID: 26491824
    [Abstract] [Full Text] [Related]

  • 9. HMGB1 is increased in adolescents with polycystic ovary syndrome (PCOS) and decreases after treatment with myo-inositol (MYO) in combination with alpha-lipoic acid (ALA).
    Cirillo F, Catellani C, Lazzeroni P, Sartori C, Tridenti G, Vezzani C, Fulghesu AM, Madeddu E, Amarri S, Street ME.
    Gynecol Endocrinol; 2020 Jul; 36(7):588-593. PubMed ID: 32054355
    [Abstract] [Full Text] [Related]

  • 10. [Evaluation of a new association between insulin-sensitizers and α-lipoic acid in obese women affected by PCOS].
    Cappelli V, Di Sabatino A, Musacchio MC, De Leo V.
    Minerva Ginecol; 2013 Aug; 65(4):425-33. PubMed ID: 24051942
    [Abstract] [Full Text] [Related]

  • 11. Modulatory role of D-chiro-inositol (DCI) on LH and insulin secretion in obese PCOS patients.
    Genazzani AD, Santagni S, Rattighieri E, Chierchia E, Despini G, Marini G, Prati A, Simoncini T.
    Gynecol Endocrinol; 2014 Jun; 30(6):438-43. PubMed ID: 24601829
    [Abstract] [Full Text] [Related]

  • 12. Alpha lipoic acid administration improved both peripheral sensitivity to insulin and liver clearance of insulin reducing potential risk of diabetes and nonalcoholic fatty liver disease in overweight/obese PCOS patients.
    Genazzani AD, Battipaglia C, Rusce L, Prampolini G, Aio C, Ricciardiello F, Foschi M, Sponzilli A, Semprini E, Petrillo T.
    Gynecol Endocrinol; 2024 Dec; 40(1):2341701. PubMed ID: 38622970
    [Abstract] [Full Text] [Related]

  • 13. Treatment with d-chiro-inositol and alpha lipoic acid in the management of polycystic ovary syndrome.
    Fruzzetti F, Capozzi A, Canu A, Lello S.
    Gynecol Endocrinol; 2019 Jun; 35(6):506-510. PubMed ID: 30612488
    [Abstract] [Full Text] [Related]

  • 14. The Effects of Myo-Inositol and D-Chiro-Inositol in a Ratio 40:1 on Hormonal and Metabolic Profile in Women with Polycystic Ovary Syndrome Classified as Phenotype A by the Rotterdam Criteria and EMS-Type 1 by the EGOI Criteria.
    Pustotina O, Myers SH, Unfer V, Rasulova I.
    Gynecol Obstet Invest; 2024 Jun; 89(2):131-139. PubMed ID: 38295772
    [Abstract] [Full Text] [Related]

  • 15. Modulatory effects of alpha-lipoic acid (ALA) administration on insulin sensitivity in obese PCOS patients.
    Genazzani AD, Shefer K, Della Casa D, Prati A, Napolitano A, Manzo A, Despini G, Simoncini T.
    J Endocrinol Invest; 2018 May; 41(5):583-590. PubMed ID: 29090431
    [Abstract] [Full Text] [Related]

  • 16. Myoinositol combined with alpha-lipoic acid may improve the clinical and endocrine features of polycystic ovary syndrome through an insulin-independent action.
    De Cicco S, Immediata V, Romualdi D, Policola C, Tropea A, Di Florio C, Tagliaferri V, Scarinci E, Della Casa S, Lanzone A, Apa R.
    Gynecol Endocrinol; 2017 Sep; 33(9):698-701. PubMed ID: 28434274
    [Abstract] [Full Text] [Related]

  • 17. Does Alpha-lipoic acid improve effects on polycystic ovary syndrome?
    Laganà AS, Monti N, Fedeli V, Gullo G, Bizzarri M.
    Eur Rev Med Pharmacol Sci; 2022 Feb; 26(4):1241-1247. PubMed ID: 35253180
    [Abstract] [Full Text] [Related]

  • 18. Effects of myo-inositol, gymnemic acid, and L-methylfolate in polycystic ovary syndrome patients.
    Stracquadanio M, Ciotta L, Palumbo MA.
    Gynecol Endocrinol; 2018 Jun; 34(6):495-501. PubMed ID: 29265900
    [Abstract] [Full Text] [Related]

  • 19. Management of women with PCOS using myo-inositol and folic acid. New clinical data and review of the literature.
    Regidor PA, Schindler AE, Lesoine B, Druckman R.
    Horm Mol Biol Clin Investig; 2018 Mar 02; 34(2):. PubMed ID: 29498933
    [Abstract] [Full Text] [Related]

  • 20. Efficacy of myo-inositol in the treatment of cutaneous disorders in young women with polycystic ovary syndrome.
    Zacchè MM, Caputo L, Filippis S, Zacchè G, Dindelli M, Ferrari A.
    Gynecol Endocrinol; 2009 Aug 02; 25(8):508-13. PubMed ID: 19551544
    [Abstract] [Full Text] [Related]

    Page: [Next] [New Search]
    of 16.